Cargando…

Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma

IMPORTANCE: Clinical trials have shown an overall survival (OS) benefit associated with first-line immunotherapy (IT) and combination targeted therapy (TT) and IT regimens compared with TT among patients with metastatic clear cell renal cell carcinoma (RCC). Generalizability of these findings in a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakiryan, Nicholas H., Jiang, Da David, Gillis, Kyle A., Green, Elizabeth, Hajiran, Ali, Hugar, Lee, Zemp, Logan, Zhang, Jingsong, Jain, Rohit K., Chahoud, Jad, Spiess, Philippe E., Sexton, Wade, Gilbert, Scott M., Manley, Brandon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150693/
https://www.ncbi.nlm.nih.gov/pubmed/34032854
http://dx.doi.org/10.1001/jamanetworkopen.2021.11329
_version_ 1783698208193511424
author Chakiryan, Nicholas H.
Jiang, Da David
Gillis, Kyle A.
Green, Elizabeth
Hajiran, Ali
Hugar, Lee
Zemp, Logan
Zhang, Jingsong
Jain, Rohit K.
Chahoud, Jad
Spiess, Philippe E.
Sexton, Wade
Gilbert, Scott M.
Manley, Brandon J.
author_facet Chakiryan, Nicholas H.
Jiang, Da David
Gillis, Kyle A.
Green, Elizabeth
Hajiran, Ali
Hugar, Lee
Zemp, Logan
Zhang, Jingsong
Jain, Rohit K.
Chahoud, Jad
Spiess, Philippe E.
Sexton, Wade
Gilbert, Scott M.
Manley, Brandon J.
author_sort Chakiryan, Nicholas H.
collection PubMed
description IMPORTANCE: Clinical trials have shown an overall survival (OS) benefit associated with first-line immunotherapy (IT) and combination targeted therapy (TT) and IT regimens compared with TT among patients with metastatic clear cell renal cell carcinoma (RCC). Generalizability of these findings in a real-world cohort outside of a clinical trial setting is unclear. OBJECTIVE: To assess the association of first-line TT, IT, and combination TT and IT regimens with OS in a real-world cohort of patients with metastatic clear cell RCC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective propensity-matched cohort study identified 5872 patients with metastatic clear cell RCC in the National Cancer Database from January 1, 2015, to December 31, 2017, who received first-line TT, IT, or combination TT and IT and were not treated on a clinical trial protocol. Patients were stratified by first-line systemic treatment. Statistical analysis was conducted from October 1 to December 1, 2020. MAIN OUTCOMES AND MEASURES: The primary outcome was OS from the date of diagnosis to death or censoring at last follow-up. After 1:1:1 nearest-neighbor caliper matching of propensity scores, survival analyses were conducted using Cox proportional hazards regression and Kaplan-Meier estimates. RESULTS: The final study population included 5872 patients (TT group: n = 4755 [81%]; 3332 men [70%]; median age, 64 years [interquartile range, 57-71 years]; IT group: n = 638 [11%]; 475 men [74%]; median age, 61 years [interquartile range, 54-69 years]; and combination TT and IT group: n = 479 [8%]; 321 men [67%]; median age, 62 years [interquartile range, 55-69 years]), and the matched cohort included 1437 patients (479 per treatment group). Patients in the IT and combination TT and IT groups were younger than those in the TT group, had fewer comorbid conditions (Charlson-Deyo score of 0, 480 of 638 [75%] in the TT group, 356 of 479 [74%] in the IT group, and 3273 of 4755 [69%] in the combination TT and IT group), and were more often treated at academic centers (315 of 638 [49%], 216 of 479 [45%], and 1935 of 4755 [41%], respectively). Both first-line IT and combination TT and IT were associated with improved OS compared with first-line TT for patients with metastatic clear cell RCC (IT group: hazard ratio [HR], 0.60 [95% CI, 0.48-0.75]; P < .001; combination TT and IT group: HR, 0.74 [95% CI, 0.60-0.91]; P = .005). No survival difference was seen between the IT and combination TT and IT groups (combination TT and IT: HR, 1.24 [95% CI, 0.98-1.56]; P = .08). CONCLUSIONS AND RELEVANCE: This study suggests that both first-line IT and combination TT and IT were associated with improved OS compared with first-line TT for patients with metastatic clear cell RCC. These findings are similar to those identified in recently reported clinical trials, lending confidence to the broader applicability of these findings outside of a clinical trial setting.
format Online
Article
Text
id pubmed-8150693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-81506932021-06-09 Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma Chakiryan, Nicholas H. Jiang, Da David Gillis, Kyle A. Green, Elizabeth Hajiran, Ali Hugar, Lee Zemp, Logan Zhang, Jingsong Jain, Rohit K. Chahoud, Jad Spiess, Philippe E. Sexton, Wade Gilbert, Scott M. Manley, Brandon J. JAMA Netw Open Original Investigation IMPORTANCE: Clinical trials have shown an overall survival (OS) benefit associated with first-line immunotherapy (IT) and combination targeted therapy (TT) and IT regimens compared with TT among patients with metastatic clear cell renal cell carcinoma (RCC). Generalizability of these findings in a real-world cohort outside of a clinical trial setting is unclear. OBJECTIVE: To assess the association of first-line TT, IT, and combination TT and IT regimens with OS in a real-world cohort of patients with metastatic clear cell RCC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective propensity-matched cohort study identified 5872 patients with metastatic clear cell RCC in the National Cancer Database from January 1, 2015, to December 31, 2017, who received first-line TT, IT, or combination TT and IT and were not treated on a clinical trial protocol. Patients were stratified by first-line systemic treatment. Statistical analysis was conducted from October 1 to December 1, 2020. MAIN OUTCOMES AND MEASURES: The primary outcome was OS from the date of diagnosis to death or censoring at last follow-up. After 1:1:1 nearest-neighbor caliper matching of propensity scores, survival analyses were conducted using Cox proportional hazards regression and Kaplan-Meier estimates. RESULTS: The final study population included 5872 patients (TT group: n = 4755 [81%]; 3332 men [70%]; median age, 64 years [interquartile range, 57-71 years]; IT group: n = 638 [11%]; 475 men [74%]; median age, 61 years [interquartile range, 54-69 years]; and combination TT and IT group: n = 479 [8%]; 321 men [67%]; median age, 62 years [interquartile range, 55-69 years]), and the matched cohort included 1437 patients (479 per treatment group). Patients in the IT and combination TT and IT groups were younger than those in the TT group, had fewer comorbid conditions (Charlson-Deyo score of 0, 480 of 638 [75%] in the TT group, 356 of 479 [74%] in the IT group, and 3273 of 4755 [69%] in the combination TT and IT group), and were more often treated at academic centers (315 of 638 [49%], 216 of 479 [45%], and 1935 of 4755 [41%], respectively). Both first-line IT and combination TT and IT were associated with improved OS compared with first-line TT for patients with metastatic clear cell RCC (IT group: hazard ratio [HR], 0.60 [95% CI, 0.48-0.75]; P < .001; combination TT and IT group: HR, 0.74 [95% CI, 0.60-0.91]; P = .005). No survival difference was seen between the IT and combination TT and IT groups (combination TT and IT: HR, 1.24 [95% CI, 0.98-1.56]; P = .08). CONCLUSIONS AND RELEVANCE: This study suggests that both first-line IT and combination TT and IT were associated with improved OS compared with first-line TT for patients with metastatic clear cell RCC. These findings are similar to those identified in recently reported clinical trials, lending confidence to the broader applicability of these findings outside of a clinical trial setting. American Medical Association 2021-05-25 /pmc/articles/PMC8150693/ /pubmed/34032854 http://dx.doi.org/10.1001/jamanetworkopen.2021.11329 Text en Copyright 2021 Chakiryan NH et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Chakiryan, Nicholas H.
Jiang, Da David
Gillis, Kyle A.
Green, Elizabeth
Hajiran, Ali
Hugar, Lee
Zemp, Logan
Zhang, Jingsong
Jain, Rohit K.
Chahoud, Jad
Spiess, Philippe E.
Sexton, Wade
Gilbert, Scott M.
Manley, Brandon J.
Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
title Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
title_full Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
title_fullStr Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
title_full_unstemmed Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
title_short Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
title_sort real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150693/
https://www.ncbi.nlm.nih.gov/pubmed/34032854
http://dx.doi.org/10.1001/jamanetworkopen.2021.11329
work_keys_str_mv AT chakiryannicholash realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT jiangdadavid realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT gilliskylea realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT greenelizabeth realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT hajiranali realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT hugarlee realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT zemplogan realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT zhangjingsong realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT jainrohitk realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT chahoudjad realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT spiessphilippee realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT sextonwade realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT gilbertscottm realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma
AT manleybrandonj realworldsurvivaloutcomesassociatedwithfirstlineimmunotherapytargetedtherapyandcombinationtherapyformetastaticclearcellrenalcellcarcinoma